Sanofi Sees Blockbuster Sales For Menactra With New Indications, Capacity
Executive Summary
Sanofi-Aventis expects new indications and additional manufacturing capacity to push its meningococcal conjugate vaccine Menactra over the €1 billion threshold in annual sales